Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
147.1 USD | -0.01% |
|
+5.91% | +11.80% |
Jul. 09 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
Jul. 03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.80% | 14.81B | |
+21.16% | 127B | |
+23.54% | 116B | |
+25.15% | 27.69B | |
-19.36% | 19.62B | |
-16.57% | 16.26B | |
-16.44% | 15.49B | |
-46.65% | 14.39B | |
+56.12% | 14.11B | |
+142.32% | 11.79B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Transcript : Neurocrine Biosciences, Inc., Q2 2023 Earnings Call, Aug 01, 2023